분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-09-20 00:22:08 , Hit : 582
 Alcoholism Gene Therapy Shows Promise


GEN News Highlights
More »
September 19, 2017


http://www.genengnews.com/gen-news-highlights/alcoholism-gene-therapy-shows-promise/81254942?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=02&utm_campaign=GEN+Daily+News+Highlights_20170919

Scientists' development could feasibly help to treat alcoholism by causing unpleasant physical side effects in individuals who imbibe. [kazan.vperemen.com/ Wilimedia]

Scientists in North and South America have developed a form of gene therapy that could feasibly help to treat alcoholism by causing unpleasant physical side effects in individuals who imbibe. The approach harnesses a short hairpin RNA (shRNA), which is delivered to liver cells using an adeno-associated viral (AAV) vector to prevent expression of a liver enzyme that is involved in metabolizing ethanol into acetate.

The researchers, headed by Anamaria C. Sanchez, Ph.D.,  from the University of Chile in Santiago, and R. Jude Samulski, Ph.D., from the University of North Carolina, Chapel Hill, conclude that their in vitro studies “suggest that gene therapy could be a useful tool for the treatment of alcoholism.” They report on their research in Human Gene Therapy, in a paper entitled, “AAV Gene Therapy for Alcoholism: Inhibition of Mitochondrial Aldehyde Dehydrogenase Enzyme Expression in Hepatoma Cells.”

Alcohol is the most commonly used addictive substance globally and causes some 3.3 million deaths every year, which approximates to 5.9% of all deaths, Prof. Sanchez and colleagues write. In the U.S., excessive alcohol consumption in 2010 was estimated to have cost the nation $250 billion, primarily due to loss in productivity, healthcare, and societal ills. There are currently three approved medications in the U.S. for treating alcohol dependence—disulfiram, naltrexone, and acamprosate. However, as Dr. Sanchez et al. point out, none is widely prescribed because they have limited efficacy, cause side effects, and patient compliance is poor.

Ethanol is metabolized in the liver in two stages: first the oxidation of ethanol to form acetaldehyde. This reaction is catalyzed by the cytosolic enzyme alcohol dehydrogenase (ADH). The acetaldehyde is then converted to acetate by a mitochondrial isoform of the enzyme aldehyde dehydrogenase, ALDH2.

About half of the Asian population has one copy of the normal ALDH2 gene and one mutant copy of the gene that encodes an inactive enzyme. These heterozygous individuals have a reduced capacity to metabolize acetaldehyde, so when they drink alcohol, the acetaldehyde accumulates in the blood and causes physical effects such as facial flushing, dizziness, hypotension, and palpitations. This is enough to prompt people to reduce their alcohol consumption and effectively prevent alcoholism.

ALDH2 is a recognized target for treating alcohol dependency. Dr. Sanchez and colleagues have now developed an shRNA that is designed to silence the expression of ALDH2 and can be delivered to cells using a self-complementary AAV2 (scAAV2) vector. They tested the shRNA in both a specially developed ALDH2-expressing human liver cell line, HEK-293/ALDH2, and to HepG2 liver cancer cells. The results showed that the vector-delivered shRNA significantly reduced ALDH2 transcript and protein levels. “In both cell lines, ALDH2 RNA levels were reduced by 90% and protein expression was inhibited by 90% and 52%, respectively, 5 days post infection,” they stated. In addition, transduced cells exposed to ethanol accumulated up to 50% higher levels of acetaldehyde than cells that weren’t treated using the shRNA.

The researchers constructed and tested five different shRNA sequences, and they chose one for use with the scAAV plasmid. They suggest that using more than one sequence could have potentially greater effects. “Further experiments could use a combination of these shRNA sequences in the search for an additive effect to knock down ALDH2 expression,” they conclude.

Commenting on the study, Human Gene Therapy editor-in-chief, Terence R. Flotte, M.D., said that substance abuse, including alcohol abuse, and associated suicide, are responsible for “an alarming increase in mortality among middle-aged Americans.” Prof. Flotte is the Celia and Isaac Haidak Professor of Medical Education and dean, provost, and executive deputy chancellor at the University of Massachusetts Medical School (Worcester, MA). “What has not often been recognized is that genetic factors account for over 79% of the risk of alcoholism, based on twin studies,” he added. “These investigators have targeted one of the best established contributors and demonstrated strong proof-of-concept data with a rAAV vector-mediated shRNA approach. This bodes well for future development of this therapy.”

Human Gene Therapy, published by Mary Ann Liebert, Inc., is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies.The above article was first published in the September 2017 issue of Human Gene Therapy with the title “AAV Gene Therapy for Alcoholism: Inhibition of Mitochondrial Aldehyde Dehydrogenase Enzyme Expression in Hepatoma Cells”. The views expressed here are those of the authors and are not necessarily those of Human Gene Therapy, Mary Ann Liebert, Inc., publishers, or their affiliates. No endorsement of any entity or technology is implied.







1227   DNA Repair Mechanism Aids Cancer by Mending Chemo Damage  이성욱 2017/11/10 569
  Alcoholism Gene Therapy Shows Promise  이성욱 2017/09/20 582
1225   CRISPR Used in Human Embryos to Probe Gene Function  이성욱 2017/09/22 584
1224   [바이오토픽] CRISPR 기반 유전자치료를 방해하는 면역계  이성욱 2018/01/10 591
1223   암 면역요법, 일부 환자에게만 효과 있는 이유  이성욱 2018/01/12 591
1222   Nature Methods retracts CRISPR study  이성욱 2018/04/10 600
1221   From Startups to Moguls] CRISPR 유전자가위 없이 편집한다? Homology Medicines  이성욱 2017/09/11 606
1220   FDA Approves Gilead CAR-T Therapy Yescarta, Plans Regenerative Medicine Policy 'Soon'  이성욱 2017/10/20 610
1219   Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals  이성욱 2018/02/01 614
1218   CRISPR System Targets RNA in Mammalian Cells  이성욱 2017/10/06 641
1217   DNA Construction  이성욱 2017/09/15 660
1216   Advisors to FDA Recommend Approval of Gene Therapy for Blindness  이성욱 2017/10/14 666
1215   2018 Lasker Award Winners: Gene Expression Researchers, Propofol Discoverer, Pioneer for RNA Biology, and Women in STEM  이성욱 2018/09/12 671
1214   [바이오토픽] 체크포인트 저해제의 부작용: 자가면역질환 초래  이성욱 2017/11/16 689
1213   First CAR T-Cell Therapy Approved in U.S.  이성욱 2017/09/01 691
1212   UPDATED: FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis  이성욱 2017/08/31 696
1211   [바이오 업계 소식: From Startups to Moguls] CRISPR-Cas9에 대한 경고와 업계 반응  이성욱 2017/06/14 702
1210   Tunable Form of CRISPR Is an Efficient Regulator of Stem Cell Expression  이성욱 2016/03/14 703
1209   Mammalian Immunity: What’s RNAi Got to Do with It?  이성욱 2017/07/25 704
1208   코오롱 인보사허가  이성욱 2017/07/12 706

[1][2] 3 [4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN